Many people have a dim view of the pharmaceutical industry, referred to by critics as the Big Pharma. This reputation is not helped by someone like Martin Shkreli, former CEO of Turing pharmaceuticals. Shkreli came under fire in 2015 when he raised the price of an anti-parasitic drug, Daraprim, from $13.50 to $750.
Daraprim can be a life-saving drug for patients with compromised immune systems like those with AIDS or cancer.
A Reuters report said Shkreli is facing trial this month but for reasons unrelated to the Daraprim price hike. Shkreli is facing fraud charges for what prosecutors say was a Ponzi-like scheme he undertook while he managed a hedge fund and a pharmaceutical company, Retrophin. He founded the drug company in 2011.
According to authorities, Shkreli lured investors into his hedge fund, which was already incurring massive losses. He allegedly lied about those losses and instead, stole millions of dollars from Retrophin to pay investors back.
On the heels of news on Shkreli, another pharmaceutical head, Barry Cadden, was sentenced to nine years in prison for conspiracy and fraud. According to CBS News, prosecutors accused Cadden of violating safety regulations at his facility, the New England Compounding Center. He supposedly did this to hasten production and increase profits.
Cadden was earlier charged with second-degree murder after contaminated medical steroids from his facility were injected into patients. Hundreds of people got sick and 76 died. Cadden was acquitted of the murder charge.
The tug-of-war between profit and public health is likely to continue as long as pharmaceutical firms are in business. One study posted in the National Center for Biotechnology Information website said the conflict of interest between the two is technically unsolvable. The study proposed an “extension of morality” in the existing system and public policy to help reconcile public good with private enterprise.
Global earnings for pharmaceutical companies are estimated at more than a trillion dollars per year. In the U.S. alone drug companies poured $790 billion into the economy. They also support 3.4 million jobs, directly and indirectly. With so much at stake, it’s unclear where this moral shift will come from.
Israel vows $284 million to resolve diamond industry’s credit crunch
The 4 percent 10-year note yield will be a floor not a ceiling
Tips for expats to set up businesses in foreign countries
The landscape for rental cars is changing — here’s why
Is the recession upon us? Think global synchronized bond collapse
Cannabis acceptance grows as hemp industry leader PotNetwork Holding breaks CBD sales records
This fast-growing organic products stock already has space on Whole Foods’ shelves
Why Vapor Group Inc. might be the breakout penny stock you’ve been looking for in 2018
The CBD industry is enjoying a boost from the lifestyle sector
When you should consult your financial advisor
Promoting women’s football in Malta by UEFA projects
Euro NCAP marks its 20th anniversary with two crash tests
European Parliament’s International Trade Committee backs CETA
The American Heart Association has released four new PSAs
PwC presents 20th global CEO survey results in Switzerland
Crypto3 days ago
Could Global Blockchain Technologies change the way we invest in cryptocurrency?
Featured4 days ago
This hemp market player’s growth is about to go into overdrive
Crypto4 days ago
One of America’s oldest gold mines enters the crypto-century
Featured5 days ago
CBD stocks emerge strong in the growing cannabis industry, marijuana legalization
Featured4 days ago
The gig economy has matured — when will the business world catch up?
Business3 days ago
Why is it becoming harder for millennials to be homeowners?
Agriculture3 days ago
The benefits of supporting sustainable palm oil
Entrepreneurship2 days ago
Why being a silver entrepreneur makes a good decision post-retirement